Trastuzumab Rezetecan

Phase 3

PPeking Union Medical College Hospital

Trastuzumab Rezetecan is one of 105 therapeutic programs targeting GEJC. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[2][1]

Indication

GEJCNot yet recruiting

Biliary Tract NeoplasmsRecruiting

UTUCRecruiting

Lung Cancer (NSCLC)Not yet recruiting

Ovarian CancerNot yet recruiting

NSCLCNot yet recruiting

Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaNot yet recruiting

HER2 + Breast CancerRecruiting

GEJCPhase 2

Not yet recruiting

Biliary Tract NeoplasmsPhase 2

Recruiting

UTUCPhase 2

Recruiting

Lung Cancer (NSCLC)Phase 2

Not yet recruiting

Ovarian CancerPhase 2

Not yet recruiting

NSCLCPhase 2

Not yet recruiting

Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaPhase 2

Not yet recruiting

HER2 + Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

88 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Hycamtin

MMeitheal

Phase 3

26 4

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 6

Femara

Novartis

Phase 3

8 7

Imfinzi

AstraZeneca

Phase 3

8 8

Opdivo

Bristol-Myers Squibb

Phase 3

8 9

Adriamycin

Pfizer

Phase 3

8 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Biliary Tract Neoplasms

NCT07704177

Phase 2Recruiting

Biliary Tract Neoplasms

NCT07670273

Q4 2028

Phase 2Not yet recruiting

GEJC

NCT07817654

Q1 2029

Phase 2Not yet recruiting

Lung Cancer (NSCLC)

NCT07699952

Q3 2029

Phase 2Recruiting

UTUC

NCT07741448

Phase 2Not yet recruiting

NSCLC

NCT07778745

Clinical

Trials by Indication[1]

HER2 + Breast Cancer2 trials

A Single-arm, Exploratory Clinical Study of Sequential Use of Regorafenib in Combination With Pegylated Tyrosine Kinase Inhibitor and Trastuzumab in Combination With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07766772·50 enrolled

Real-world Study of Pyrotinib-containing Regimens in First-line or Second-line Treatment of Advanced HER2-positive Breast Cancer

Recruiting·PPeking University People's Hospital·Approved·NCT07600164·500 enrolled

Biliary Tract Neoplasms2 trials

A Prospective, Open-Label, Multicenter Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib for HER2-Positive or Low-Expression Locally Advanced or Metastatic Biliary Tract Cancer in the Second-Line or Later Setting

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07704177·70 enrolled

A Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07670273·70 enrolled

GEJC1 trial

Prospective, Exploratory Clinical Study of Trastuzumab Combined With Retlirafusp Alfa in Treating HER2 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07817654·35 enrolled

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma1 trial

A Multicenter, Randomized Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX Regimen for Perioperative Treatment of Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07802288·80 enrolled

NSCLC1 trial

A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07778745·37 enrolled

3 more indications

Ovarian Cancer1 trial

Trastuzumab Rezetecan and Carboplatin With or Without Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer: an Open-label, Multicenter, Randomized Controlled Phase II Study

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07776171·176 enrolled

Lung Cancer (NSCLC)1 trial

First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations

Not yet recruiting·YYongsheng Wang·Phase 2·NCT07699952·35 enrolled

UTUC1 trial

An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate Neoadjuvant Gemcitabine Combined With Trastuzumab Rezetecan in HER2-positive Upper Tract Urothelial Carcinoma

Recruiting·ZZhiquan Hu·Phase 2·NCT07741448·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Trastuzumab Rezetecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trastuzumab Rezetecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: PPeking Union Medical College Hospital

Trastuzumab Rezetecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Q1 2029

Q3 2029

Trials by Indication[1]

HER2 + Breast Cancer2 trials

Biliary Tract Neoplasms2 trials

GEJC1 trial

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma1 trial

NSCLC1 trial

Ovarian Cancer1 trial

Lung Cancer (NSCLC)1 trial

UTUC1 trial

References

Drug Info

Quick Facts

Related News